These findings suggest that pharmacological inhibition of PRMT5 effectively curbs the growth of prostate cancer cells and tumors, positioning ZMYND11 as a potential predictive biomarker for improving the clinical management of patients. This evidence concerns the gene ZMYND11 and Familial prostate cancer.